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Figure S2
. Comparison of survival outcomes in patients with advanced LADC according to treatment regimen. Advanced LADC patients receiving BEV/CHT showed significantly higher median OS compared to those treated with CHT only (median OSs were 24 vs. 10 months, respectively, p < 0.0001, log-rank test). Figure S3 . Kaplan-Meier curves for the OS of LADC patients treated with CHT alone and LADC patients with KRAS G12D mutations in the BEV/CHT sub-cohort. Patients with tumors harboring KRAS G12D mutations and treated with BEV/CHT had comparable OS to that of patients with KRAS WT or KRAS mutant tumors in the CHT alone sub-cohort. 
